ErbB-inhibitory protein: a modified ectodomain of epidermal growth factor receptor synergizes with dasatinib to inhibit growth of breast cancer cells.

MLA

Nautiyal, Jyoti, et al. “ErbB-Inhibitory Protein: A Modified Ectodomain of Epidermal Growth Factor Receptor Synergizes with Dasatinib to Inhibit Growth of Breast Cancer Cells.” Molecular Cancer Therapeutics, vol. 9, no. 6, June 2010, pp. 1503–14. EBSCOhost, https://doi.org/10.1158/1535-7163.MCT-10-0019.

APA

Nautiyal, J., Yu, Y., Aboukameel, A., Kanwar, S. S., Das, J. K., Du, J., Patel, B. B., Sarkar, F. H., Rishi, A. K., Mohammad, R. M., & Majumdar, A. P. N. (2010). ErbB-inhibitory protein: a modified ectodomain of epidermal growth factor receptor synergizes with dasatinib to inhibit growth of breast cancer cells. Molecular Cancer Therapeutics, 9(6), 1503–1514. https://doi.org/10.1158/1535-7163.MCT-10-0019

Chicago

Nautiyal, Jyoti, Yingjie Yu, Amro Aboukameel, Shailender S Kanwar, Jayanta K Das, Jianhua Du, Bhaumik B Patel, et al. 2010. “ErbB-Inhibitory Protein: A Modified Ectodomain of Epidermal Growth Factor Receptor Synergizes with Dasatinib to Inhibit Growth of Breast Cancer Cells.” Molecular Cancer Therapeutics 9 (6): 1503–14. doi:10.1158/1535-7163.MCT-10-0019.